What does EirGenix, Inc. do?

EirGenix, Inc. (6589.TW) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 6589.TW's market cap?

EirGenix, Inc. (6589.TW) has a market capitalization of approximately $15.44 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does 6589.TW pay a dividend?

No — EirGenix, Inc. (6589.TW) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 6589.TW profitable?

EirGenix, Inc. (6589.TW) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

6589.TW

EirGenix, Inc.

TAI·Biotechnology · Healthcare

NT$50.50NT$0.80+1.61%

Market capNT$15.44B·Aug 26 5:30 AM UTC

Price Chart

NT$50.50+NT$0.80 (+1.61%)today

−60.55%CAGR −16.98%

Select date range

FromTo

Nov 23, 2016Aug 26, 2021 → Aug 26, 2026· 5.0 yrsAug 26, 2026

Key Metrics

6589.TW does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings DateNov 18

Last Report DateAug 12

Reported vs Estimate−NT$0.02 vs −NT$0.70

Earnings Surprise+96.9%

Income Statement Flow

PRO

See exactly how 6589.TW's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 6589.TW and 80,000+ other tickers.

About EirGenix, Inc.

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for…

CEO: Li Cheng Liu
Sector: Healthcare
Industry: Biotechnology
Exchange: TAI
Employees: 1,000
Website: www.eirgenix.com

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 6589.TW

What does EirGenix, Inc. do?: EirGenix, Inc. (6589.TW) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 6589.TW's market cap?: EirGenix, Inc. (6589.TW) has a market capitalization of approximately $15.44 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does 6589.TW pay a dividend?: No — EirGenix, Inc. (6589.TW) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 6589.TW profitable?: EirGenix, Inc. (6589.TW) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.